80% of breast cancer patients unnecessary chemotherapy
Here to remind a female friend were 80% of breast cancer, breast cancer chemotherapy in patients with completely unnecessary.
As a women's nightmare, if early detection of breast cancer can be cured. But for the measures taken to prevent recurrence but is something wrong. Because experts believe that 70% of the introduction of mastectomy for women must continue to receive chemotherapy, to prevent remove lesions, cancer metastasis and recurrence. But the reality is that this chemotherapy, 80% of the patients is totally unnecessary! In other words, this 80% of the women's best not to arrange chemotherapy. French Institute for Breast Disease Committee Suzette Delaloge people, cancer experts and Syria Zete De Laloge (Suzette Delaloge) admitted: "breast cancer recurrence rate of about 20%. Therefore, it is a lot of women experienced their present do not need chemotherapy. "But she was also known as:" Today, people think it is to cope with the price. "incomparably heavy price! Heavy chemotherapy not only costly from an economic point of view - the use of valuable drugs, but also have serious side effects (hair loss, digestive disorders, cardiovascular complications, infections ... ...), bring different levels of psychological pain. Some drugs can even cause fatal secondary leukemia, or lead to heart failure, although these are rare, and less and less.
80% ... ... such a high proportion of medical research will naturally be an effort to zero, or at least reduced to acceptable levels. This means that it accurately identified 20% of women have to accept chemotherapy. Fortunately, an ongoing trial show that the prognosis is expected to change the pattern of testing. First of all is worth mentioning that Mammaprint. The study began in 2002, and in 2007 became the first to receive U.S. Food and Drug Administration (FDA) approved a similar test is applicable to all breast cancer (regardless of whether they are hormone related). Preliminary results show that the test will help to better identify which women's risk of relapse for doctors to "downgrade treatment" to provide a basis.
This is a real challenge. Because at present, to decide whether patients need to be complemented by postoperative chemotherapy, cancer experts only on the basis of the size and nature of the tumor, the patient's age, hormone receptor characteristics, axillary lymph node metastasis in this cancer, the first such factors as the number of lesions Inn to assess the risk of diversion. "While these standards is effective for large crowds, but the individual level is still insufficient." Curie Institute in Paris Surgeons Fabijan reais (Fabien Reyal) explained, "should look for and the development of even more sophisticated technology tools. "a way out from deciphering the human genome, especially genes involved in tumor and metastasis research.
On this basis, the Netherlands, the researchers developed a Mammaprint. It was a can simultaneously analyze 70 cancer genes in DNA chips (see diagram). Using this tool, we will be able to understand each patient's individual gene expression profiles to predict recurrence risk. Actual operation, when the surgeon removed the breast tumor, after waiting for the pathologist in the operating room soon will be a small piece of frozen tumor sections. "The future of medicine is one of the goals between the different technical departments of professional and quick cooperation." Syria Zete De Laloge excited about that. Tumor samples were then sent to the operating Mammaprint test pharmaceutical company Agendia BV of the Netherlands for analysis.
From 2008 onwards, Mammaprint already on sale in the United States. However, in Europe, it is still in the testing phase, to prove that their relative advantages of the traditional analysis methods. This is because the "Amsterdam criteria" summary based on just those patients with known duration of frozen tumor tissue samples only. However, with the assessment of the risk of recurrence compared with traditional methods, Mammaprint or will the proportion of high-risk patients decreased by 10% or more (74% traditional methods, this method is 63%). At first glance this proportion negligible, but in absolute terms, it involves many, many women, is an important step towards treating relegated. This is only the beginning.
Indeed, in order foolproof, a new comparison test is being launched in Europe. As with previous retrospective testing the contrary, this vision of real-time tests will be compared with the traditional Mammaprint recurrence risk assessment accuracy. To this end, cancer experts will recruit 6,000 women around the world. For each of a patient, if the current methods and Mammaprint have shown that the risk of relapse, it will be subjected to chemotherapy; less risky if the two come to the conclusion, are no longer chemotherapy. However, if the conclusions of these two methods are inconsistent, then randomly decided to approach patients, some of the conclusions will be subject to traditional methods, some Zeyi Mammaprint prevail. "Up to now, Mammaprint performance should be better than any clinical criteria, the risk is very low." Comparison test in France, the coordination of the Syrian-Zete De Laloge said. Recruitment of patients is expected to end in 2 to 3 years, while the comparative results were out until 5 years after Zexu.
